X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will be used for a clinical phase III trial for a fixed-dose combination of artemether-lumefantrine-amodiaquine drug (three existing antimalarial drugs already developed, marketed and sold) against malaria.
Lead Product(s): Artemether,Lumefantrine,Amodiaquine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GHIT Fund
Deal Size: $3.3 million Upfront Cash: Undisclosed
Deal Type: Financing December 13, 2023
Details:
Vyleesi (bremelanotide injection) is a melanocortin receptor (MCR) agonist that is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Vyleesi
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Palatin Technologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
The agreement provides Fosun Pharma the rights to develop and commercialize Ardelyx's lead product, tenapanor, in China for the treatment of patients with irritable bowel syndrome with constipation and for the treatment of hyperphosphatemia related to chronic kidney disease.
Lead Product(s): Tenapanor
Therapeutic Area: Nephrology Product Name: Xphozah
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Ardelyx
Deal Size: $125.0 million Upfront Cash: $12.0 million
Deal Type: Licensing Agreement July 13, 2023
Details:
Artesun (artesunate) is rapidly metabolized into an active metabolite DHA which contains an endoperoxide bridge that is activated by heme iron leading to oxidative stress, inhibition of protein and nucleic acid synthesis, which decreases parasite growth and survival.
Lead Product(s): Artemisinin-based Antimalarial Drug
Therapeutic Area: Infections and Infectious Diseases Product Name: Artesun
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Details:
Hansizhuang (serplulimab), a recombinant humanised anti-PD-1 monoclonal antibody injection, is the first innovative monoclonal antibody developed by Henlius for the treatment of MSI-H solid tumours and squamous non-small cell lung cancer (sqNSCLC).
Lead Product(s): Serplulimab
Therapeutic Area: Oncology Product Name: Hansizhuang
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Shanghai Henlius Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 07, 2023
Details:
HANSIZHUANG (serplulimab), a recombinant humanised anti-PD-1 monoclonal antibody injection, is the first innovative monoclonal antibody developed by Henlius for the first-line treatment of SCLC.
Lead Product(s): Serplulimab
Therapeutic Area: Oncology Product Name: Hansizhuang
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Shanghai Henlius Biotech
Deal Size: Undisclosed Upfront Cash: $143.6 million
Deal Type: Licensing Agreement December 27, 2022
Details:
The results suggest that a booster dose of the Omicron BA.4/BA.5-adapted bivalent vaccine Comirnaty (tozinameran) may induce a higher level of protection against the Omicron BA.4 and BA.5 sublineages than the companies’ monovalent COVID-19 vaccine.
Lead Product(s): Tozinameran
Therapeutic Area: Infections and Infectious Diseases Product Name: Comirnaty
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: BioNTech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2022
Details:
Pre-clinical data showed a booster dose of Omicron BA.4/BA.5-adapted bivalent vaccine generated a strong neutralizing antibody response against Omicron BA.1, BA.2 and BA.4/BA.5 variants, as well as the original wild-type strain.
Lead Product(s): Omicron BA.4/BA.5-adapted Bivalent Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: BioNTech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
Under the Agreement Neovii is entitled to receive upfront, regulatory and commercial sales milestones as well as proceeds from supplying Grafalon® (Rabbit Anti-human T-lymphocyte Globulin) to Fosun Pharma Industry.
Lead Product(s): Rabbit Anti-human T-lymphocyte Globulin
Therapeutic Area: Immunology Product Name: Grafalon
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Neovii
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 07, 2022
Details:
Helsinn will grant Fosun an exclusive license to distribute, promote and sell the following products in the aforesaid territory: Aloxi (Palonosetron hydrochloride), Akynzeo (Netupitant and Palonosetron hydrochloride) and NEPA (Fosnetupitant and Palonosetron hydrochloride).
Lead Product(s): Palonosetron
Therapeutic Area: Gastroenterology Product Name: Aloxi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Helsinn Advanced Synthesis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 12, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
